William Blair Analysts Lift Earnings Estimates for LRMR

Key Points

• William Blair has increased its Q3 2025 EPS estimate for Larimar Therapeutics to ($0.47), improving from the previous estimate of ($0.53).
• Despite the recent upgrade, Larimar's stock has recently seen a 5.9% decline, opening at $4.01, with a year-to-date high of $9.50.
• Institutional investors own 91.92% of Larimar's shares, indicating strong institutional confidence in the company.

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - William Blair boosted their Q3 2025 EPS estimates for shares of Larimar Therapeutics in a research report issued on Thursday, August 14th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($0.47) for the quarter, up from their previous estimate of ($0.53). The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics' Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.69) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.50) EPS.

Several other equities research analysts have also issued reports on LRMR. Citigroup restated a "buy" rating on shares of Larimar Therapeutics in a report on Tuesday, June 24th. Guggenheim reaffirmed a "buy" rating and issued a $26.00 price target on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. Wedbush reduced their price target on shares of Larimar Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a research note on Tuesday, June 24th. Finally, JMP Securities reduced their price target on shares of Larimar Therapeutics from $22.00 to $18.00 and set a "market outperform" rating on the stock in a research note on Friday. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $18.43.

Larimar Therapeutics Trading Down 5.9%

Larimar Therapeutics stock opened at $4.01 on Monday. The firm has a 50-day moving average price of $3.29 and a 200-day moving average price of $2.77. The firm has a market capitalization of $331.95 million, a PE ratio of -2.57 and a beta of 0.93. Larimar Therapeutics has a 12-month low of $1.61 and a 12-month high of $9.50.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.06.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LRMR. Wells Fargo & Company MN increased its position in Larimar Therapeutics by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 19,657 shares of the company's stock valued at $76,000 after purchasing an additional 6,701 shares during the period. Envestnet Asset Management Inc. boosted its holdings in shares of Larimar Therapeutics by 12.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 35,525 shares of the company's stock valued at $137,000 after buying an additional 3,877 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Larimar Therapeutics by 45.1% in the 4th quarter. Renaissance Technologies LLC now owns 513,542 shares of the company's stock valued at $1,987,000 after buying an additional 159,700 shares in the last quarter. Barclays PLC boosted its holdings in shares of Larimar Therapeutics by 17.3% in the 4th quarter. Barclays PLC now owns 70,425 shares of the company's stock valued at $273,000 after buying an additional 10,393 shares in the last quarter. Finally, XTX Topco Ltd boosted its holdings in shares of Larimar Therapeutics by 316.3% in the 4th quarter. XTX Topco Ltd now owns 63,810 shares of the company's stock valued at $247,000 after buying an additional 48,481 shares in the last quarter. Hedge funds and other institutional investors own 91.92% of the company's stock.

Insider Buying and Selling

In other Larimar Therapeutics news, Director James E. Flynn bought 9,375,000 shares of the business's stock in a transaction on Thursday, July 31st. The shares were acquired at an average price of $3.20 per share, with a total value of $30,000,000.00. Following the transaction, the director owned 9,538,945 shares of the company's stock, valued at approximately $30,524,624. This trade represents a 5,718.38% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 4.50% of the company's stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.